RU2196139C2 - 1,4,5-тризамещенные производные имидазола, способы их получения и фармацевтическая композиция на их основе - Google Patents

1,4,5-тризамещенные производные имидазола, способы их получения и фармацевтическая композиция на их основе Download PDF

Info

Publication number
RU2196139C2
RU2196139C2 RU97113753/04A RU97113753A RU2196139C2 RU 2196139 C2 RU2196139 C2 RU 2196139C2 RU 97113753/04 A RU97113753/04 A RU 97113753/04A RU 97113753 A RU97113753 A RU 97113753A RU 2196139 C2 RU2196139 C2 RU 2196139C2
Authority
RU
Russia
Prior art keywords
formula
alkyl
imidazole
compound
fluorophenyl
Prior art date
Application number
RU97113753/04A
Other languages
English (en)
Russian (ru)
Other versions
RU97113753A (ru
Inventor
Джерри Лерой ЭДАМС (US)
Джерри Лерой ЭДАМС
Тимоти Ф. ГАЛЛАГЕР (US)
Тимоти Ф. ГАЛЛАГЕР
Рави Шанкер ГАРИДЖИПАТИ (IN)
Рави Шанкер ГАРИДЖИПАТИ
Джеффри Чарльз БОЕМ (US)
Джеффри Чарльз БОЕМ
Джозеф СИСКО (US)
Джозеф Сиско
Джон Чеунг-Лун ЛИ (US)
Джон Чеунг-Лун ЛИ
Original Assignee
Смитклайн Бичам Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смитклайн Бичам Корпорейшн filed Critical Смитклайн Бичам Корпорейшн
Publication of RU97113753A publication Critical patent/RU97113753A/ru
Application granted granted Critical
Publication of RU2196139C2 publication Critical patent/RU2196139C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
RU97113753/04A 1995-01-09 1996-01-11 1,4,5-тризамещенные производные имидазола, способы их получения и фармацевтическая композиция на их основе RU2196139C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36996495A 1995-01-09 1995-01-09
US08/369,964 1995-06-07
US08/472,366 1995-06-07
US08/472,366 US5593992A (en) 1993-07-16 1995-06-07 Compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2002122174/14A Division RU2002122174A (ru) 1995-01-09 2002-08-15 Способ профилактики и лечения заболевания, опосредуемого csbp/rk/p38 киназой, и способ лечения воспаления

Publications (2)

Publication Number Publication Date
RU97113753A RU97113753A (ru) 1999-06-20
RU2196139C2 true RU2196139C2 (ru) 2003-01-10

Family

ID=27004764

Family Applications (2)

Application Number Title Priority Date Filing Date
RU97113753/04A RU2196139C2 (ru) 1995-01-09 1996-01-11 1,4,5-тризамещенные производные имидазола, способы их получения и фармацевтическая композиция на их основе
RU2002122174/14A RU2002122174A (ru) 1995-01-09 2002-08-15 Способ профилактики и лечения заболевания, опосредуемого csbp/rk/p38 киназой, и способ лечения воспаления

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2002122174/14A RU2002122174A (ru) 1995-01-09 2002-08-15 Способ профилактики и лечения заболевания, опосредуемого csbp/rk/p38 киназой, и способ лечения воспаления

Country Status (33)

Country Link
US (5) US5593992A (OSRAM)
EP (2) EP0809499B1 (OSRAM)
JP (2) JP3330952B2 (OSRAM)
CN (1) CN1138546C (OSRAM)
AP (1) AP1270A (OSRAM)
AR (1) AR002267A1 (OSRAM)
AT (1) ATE254613T1 (OSRAM)
AU (1) AU705207C (OSRAM)
BG (1) BG63769B1 (OSRAM)
BR (1) BR9606904A (OSRAM)
CA (1) CA2209938A1 (OSRAM)
CZ (1) CZ215897A3 (OSRAM)
DE (1) DE69630777T2 (OSRAM)
DK (1) DK0809499T3 (OSRAM)
DZ (1) DZ1961A1 (OSRAM)
ES (1) ES2210348T3 (OSRAM)
FI (1) FI972901L (OSRAM)
HU (1) HUP9702409A3 (OSRAM)
ID (3) ID23273A (OSRAM)
IL (7) IL134324A (OSRAM)
IN (3) IN184957B (OSRAM)
MA (1) MA23770A1 (OSRAM)
MX (1) MX9705142A (OSRAM)
NO (3) NO973167L (OSRAM)
NZ (1) NZ301204A (OSRAM)
OA (1) OA10738A (OSRAM)
PL (1) PL322249A1 (OSRAM)
PT (1) PT809499E (OSRAM)
RU (2) RU2196139C2 (OSRAM)
SI (1) SI0809499T1 (OSRAM)
SK (1) SK90297A3 (OSRAM)
TW (1) TW523511B (OSRAM)
WO (1) WO1996021452A1 (OSRAM)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2401265C2 (ru) * 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
RU2418582C1 (ru) * 2010-04-08 2011-05-20 Аверин Константин Михайлович 1,3-диалкилбензимидазолия галогениды - средства для лечения рассеянного склероза
RU2475483C2 (ru) * 2006-04-20 2013-02-20 Янссен Фармацевтика Н.В. Ингибиторы с-fms киназы
RU2813203C2 (ru) * 2019-08-23 2024-02-07 Мотида Фармасьютикал Ко., Лтд. Способ получения гетероциклиденового ацетамидного производного
US12286414B2 (en) 2019-08-23 2025-04-29 Mochida Pharmaceutical Co., Ltd. Method for producing heterocyclidene acetamide derivative

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
JP3377529B2 (ja) * 1993-09-17 2003-02-17 スミスクライン・ビーチャム・コーポレイション 薬物結合タンパク質
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
MX9705296A (es) * 1995-01-12 1997-10-31 Smithkline Beecham Corp Compuestos novedosos de imidazol 1,4,5-susbtituidos y el uso de los mismos para preparar composiciones para uso en terapia.
EP0737471A3 (fr) * 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
FR2740341B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
ZA9610687B (en) 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
IL125223A0 (en) * 1996-01-11 1999-03-12 Smithkline Beecham Corp Novel substituted imidazole compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
WO1997032583A1 (en) * 1996-03-08 1997-09-12 Smithkline Beecham Corporation Use of csaidtm compounds as inhibitors of angiogenesis
US6096739A (en) * 1996-03-25 2000-08-01 Smithkline Beecham Corporation Treatment for CNS injuries
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
ES2215242T3 (es) 1996-11-19 2004-10-01 Amgen Inc. Agentes antiinflamatorios de pirrol condensado sustituido con arilo y heteroarilo.
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
AP999A (en) * 1997-01-10 2001-08-11 Smithkline Beecham Corp Novel substituted imidazole compounds.
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
BR9808998A (pt) 1997-04-24 2000-08-08 Ortho Mcneil Pharm Inc Imidazóis substituìdos úteis no tratamento de doenças inflamatórias
EP1000055A1 (en) * 1997-05-22 2000-05-17 G.D. Searle & Co. SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
US6087496A (en) * 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
PL336990A1 (en) * 1997-05-22 2000-07-31 Searle & Co 3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
JP2002502380A (ja) 1997-05-22 2002-01-22 ジー．ディー．サール アンド カンパニー ｐ３８キナーゼ阻害剤としてのピラゾール誘導体
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
DE69835518T2 (de) 1997-06-12 2007-08-09 Aventis Pharma Ltd., West Malling Imidazolyl-cyclische acetale
EP1023066A4 (en) 1997-06-13 2001-05-23 Smithkline Beecham Corp NEW PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUND
JP2002505690A (ja) 1997-06-19 2002-02-19 スミスクライン・ビーチャム・コーポレイション 新規なアリールオキシピリミジン置換イミダゾール化合物
AU8757098A (en) * 1997-06-30 1999-02-10 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
EP1019396A1 (en) * 1997-07-02 2000-07-19 SmithKline Beecham Corporation Novel cycloalkyl substituted imidazoles
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
AR016294A1 (es) * 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
WO1999017776A1 (en) * 1997-10-08 1999-04-15 Smithkline Beecham Corporation Novel cycloalkenyl substituted compounds
WO1999018942A1 (en) * 1997-10-10 1999-04-22 Imperial College Innovations Ltd. Use of csaidtm compounds for the management of uterine contractions
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US7041694B1 (en) 1997-12-17 2006-05-09 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
CA2314980A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
BR9910621A (pt) 1998-05-22 2001-01-30 Smithkline Beecham Corp Novos compostos de imidazol 2-alquil substituìdos
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
CA2333157A1 (en) * 1998-05-26 1999-12-02 Smithkline Beecham Corporation Novel substituted imidazole compounds
AU4395399A (en) * 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
ATE266399T1 (de) 1998-08-20 2004-05-15 Smithkline Beecham Corp Neue substituierte triazolverbindungen
EP1126852B1 (en) 1998-11-04 2004-01-21 SmithKline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
WO2000040243A1 (en) 1999-01-08 2000-07-13 Smithkline Beecham Corporation Novel compounds
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
JP2003502424A (ja) * 1999-06-17 2003-01-21 シオノギ バイオリサーチ コーポレイション Ｉｌ−１２産生の阻害物質
IL137365A0 (en) * 1999-07-21 2001-07-24 Sankyo Co Heteroaryl-substituted pyrrole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
EP1233950B1 (en) 1999-11-23 2005-10-05 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
WO2001038312A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
US20020002169A1 (en) * 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
DE60016191T2 (de) * 1999-12-08 2005-12-22 Pharmacia Corp., Chicago Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP1299123A2 (en) * 2000-07-13 2003-04-09 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
WO2002007721A2 (en) 2000-07-20 2002-01-31 Lauras As Use of cox-2 inhibitors for preventing immunodeficiency
NZ524806A (en) 2000-10-23 2006-03-31 Smithkline Beecham Corp Tri-substituted 8H-pyrido[2,3-d]pyrimidin-7-one compounds
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
ES2296910T3 (es) * 2001-01-22 2008-05-01 Sankyo Company, Limited Compuestos sustituidos con grupo amino biciclicos.
NZ528405A (en) 2001-03-26 2005-07-29 Ortho Mcneil Pharm Inc Process for the preparation of tetrasubstituted imidazole derivatives and novel crystalline structures thereof
MY137736A (en) 2001-04-03 2009-03-31 Pharmacia Corp Reconstitutable parenteral composition
WO2002094267A1 (fr) * 2001-05-24 2002-11-28 Sankyo Company, Limited Preparation pharmaceutique pour prevenir ou traiter l'arthrite
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
JP4432492B2 (ja) * 2001-10-22 2010-03-17 田辺三菱製薬株式会社 ４−イミダゾリン−２−オン化合物
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
US6982259B2 (en) * 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
CA2492033A1 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
AU2003262911A1 (en) 2002-08-29 2004-03-19 Scios Inc. Methods of promoting osteogenesis
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
WO2004041210A2 (en) 2002-11-05 2004-05-21 Smithkline Beecham Corporation Antibacterial agents
US7524955B2 (en) * 2002-12-16 2009-04-28 Astrazeneca Uk Limited Process for the preparation of pyrimidine compounds
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
WO2005030091A2 (en) 2003-09-25 2005-04-07 Scios Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US7576215B2 (en) * 2003-12-12 2009-08-18 Wyeth Quinolines and pharmaceutical compositions thereof
CA2550064A1 (en) * 2003-12-18 2005-07-07 Pfizer Products Inc. Methods of treating acute inflammation in animals with p38 map kinase inhibitors
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
JP4792396B2 (ja) * 2004-08-31 2011-10-12 三洋化成工業株式会社 界面活性剤
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
CN101495475A (zh) * 2005-03-25 2009-07-29 葛兰素集团有限公司 制备吡啶并[2,3-d]嘧啶-7-酮和3,4-二氢嘧啶并[4,5-d]嘧啶-2(1H)-酮衍生物的方法
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
TW200720272A (en) * 2005-04-22 2007-06-01 Kalypsys Inc Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
PL2021335T3 (pl) 2006-04-20 2011-10-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory kinazy C-FMS
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2173876A4 (en) * 2007-06-05 2012-05-30 Western States Biopharmaceuticals Inc T CELL CYTOKIN INDUCING SURFACE MOLECULES AND USE METHOD
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
EP2393514B1 (en) * 2009-02-06 2017-12-20 Sichuan Huiyu Pharmaceutical Co., Ltd. Dual inhibition of immunophilin/cyclophilin and emmprin immunoglobulin receptor superfamily members
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
IN2015DN00659A (OSRAM) 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
EA201590380A1 (ru) * 2012-08-16 2015-07-30 Янссен Фармацевтика Нв Замещенные пиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
CN104496906B (zh) * 2014-11-05 2016-03-23 上海浩登材料科技有限公司 一种咪唑的制备方法
CN104402823B (zh) * 2014-11-05 2016-03-23 上海浩登材料科技有限公司 一种1，2-二甲基咪唑的制备方法
CN113350353A (zh) 2015-03-23 2021-09-07 墨尔本大学 呼吸性疾病的治疗
WO2018201192A1 (en) * 2017-05-03 2018-11-08 The University Of Melbourne Compounds for the treatment of respiratory diseases
LT3691620T (lt) 2017-10-05 2022-09-26 Fulcrum Therapeutics, Inc. P38 kinazės inhibitoriai, sumažinantys dux4 ir pasrovinių genų raišką, skirti fshd gydymui
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN113272298B (zh) * 2018-11-07 2025-04-18 天莅生物技术有限公司 用于治疗呼吸系统疾病的化合物和组合物
EP3725768A1 (en) 2019-04-17 2020-10-21 Newron Pharmaceuticals S.p.A. Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives
FR3097222B1 (fr) * 2019-06-11 2021-05-28 Michelin & Cie Nouveaux composes 1,3-dipolaires comprenant un heterocycle aromatique et un cycle imidazole

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461770A (en) * 1978-04-11 1984-07-24 Ciba-Geigy Corporation Mercaptoimidazole derivatives
US4822805A (en) * 1986-08-15 1989-04-18 Fujisawa Pharmaceutical Co., Ltd. Pyridyl-imidazole compounds which have useful pharmaceutical activity
US5166400A (en) * 1989-01-19 1992-11-24 Pfizer Inc. Intermediates for isopropyl 3S-amino-2R-hydroxy-alkanoates
WO1996001806A1 (en) * 1994-07-12 1996-01-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Glycinamide derivatives, pharmaceutical compositions containing the same and methods utilizing the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU383303A3 (OSRAM) * 1969-03-11 1973-05-25
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en) * 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
CA1175431A (en) * 1980-07-25 1984-10-02 Alfred Sallmann Tri-substituted imidazole derivatives, processes for their manufacture, pharmaceutical preparations containing them, and their use
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IE59893B1 (en) * 1986-04-16 1994-04-20 Roussel Uclaf Process for the manufacture of n-(sulfonylmethyl) formamides
WO1992010190A1 (en) * 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids
WO1992010498A1 (en) * 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids
EP0624159B1 (en) * 1992-01-13 1998-11-25 Smithkline Beecham Corporation Pyridyl substituted imidazoles
MX9300141A (es) * 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
ZA945363B (en) * 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds
MX9705296A (es) * 1995-01-12 1997-10-31 Smithkline Beecham Corp Compuestos novedosos de imidazol 1,4,5-susbtituidos y el uso de los mismos para preparar composiciones para uso en terapia.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461770A (en) * 1978-04-11 1984-07-24 Ciba-Geigy Corporation Mercaptoimidazole derivatives
US4822805A (en) * 1986-08-15 1989-04-18 Fujisawa Pharmaceutical Co., Ltd. Pyridyl-imidazole compounds which have useful pharmaceutical activity
US5166400A (en) * 1989-01-19 1992-11-24 Pfizer Inc. Intermediates for isopropyl 3S-amino-2R-hydroxy-alkanoates
WO1996001806A1 (en) * 1994-07-12 1996-01-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Glycinamide derivatives, pharmaceutical compositions containing the same and methods utilizing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Д.Р.ЛОУРЕНС и др. Клиническая фармакология. - М.: Медицина, 1993, стр.87-114, 469-505. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2401265C2 (ru) * 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
RU2475483C2 (ru) * 2006-04-20 2013-02-20 Янссен Фармацевтика Н.В. Ингибиторы с-fms киназы
RU2418582C1 (ru) * 2010-04-08 2011-05-20 Аверин Константин Михайлович 1,3-диалкилбензимидазолия галогениды - средства для лечения рассеянного склероза
RU2813203C2 (ru) * 2019-08-23 2024-02-07 Мотида Фармасьютикал Ко., Лтд. Способ получения гетероциклиденового ацетамидного производного
US12286414B2 (en) 2019-08-23 2025-04-29 Mochida Pharmaceutical Co., Ltd. Method for producing heterocyclidene acetamide derivative

Also Published As

Publication number Publication date
BG101727A (bg) 1998-03-31
NO973167L (no) 1997-09-08
ATE254613T1 (de) 2003-12-15
IN188339B (OSRAM) 2002-09-07
AP1270A (en) 2004-04-16
PL322249A1 (en) 1998-01-19
EP0809499A4 (en) 1998-10-14
ID23597A (id) 1996-10-10
JPH10512555A (ja) 1998-12-02
US6103936A (en) 2000-08-15
WO1996021452A1 (en) 1996-07-18
IN188338B (OSRAM) 2002-09-07
IL116455A0 (en) 1996-03-31
SK90297A3 (en) 1998-01-14
EP0809499B1 (en) 2003-11-19
NO973167D0 (no) 1997-07-08
DK0809499T3 (da) 2004-03-29
IL134323A (en) 2001-11-25
OA10738A (en) 2002-12-11
DE69630777T2 (de) 2004-07-29
NO20016225D0 (no) 2001-12-19
US6222036B1 (en) 2001-04-24
FI972901A0 (fi) 1997-07-08
IL134323A0 (en) 2001-04-30
HUP9702409A3 (en) 1999-06-28
IL116455A (en) 2001-07-24
PT809499E (pt) 2004-04-30
IN184957B (OSRAM) 2000-10-07
IL134322A (en) 2001-09-13
TW523511B (en) 2003-03-11
JP3330952B2 (ja) 2002-10-07
AR002267A1 (es) 1998-03-11
CA2209938A1 (en) 1996-07-18
IL134324A (en) 2001-08-26
MX9705142A (es) 1997-10-31
BR9606904A (pt) 1997-10-21
CZ215897A3 (cs) 1998-04-15
ES2210348T3 (es) 2004-07-01
AU705207B2 (en) 1999-05-20
FI972901A7 (fi) 1997-09-08
IL134324A0 (en) 2001-04-30
AU705207C (en) 2002-09-19
MA23770A1 (fr) 1996-10-01
ID23599A (id) 1996-10-10
NZ301204A (en) 1999-05-28
US20020188122A1 (en) 2002-12-12
SI0809499T1 (en) 2004-04-30
EP1264827A1 (en) 2002-12-11
NO20016225L (no) 1997-09-08
NO20016226D0 (no) 2001-12-19
EP0809499A1 (en) 1997-12-03
AU4657296A (en) 1996-07-31
FI972901L (fi) 1997-09-08
ID23273A (id) 1996-10-10
IL134322A0 (en) 2001-04-30
US5663334A (en) 1997-09-02
US5593992A (en) 1997-01-14
BG63769B1 (bg) 2002-12-29
AP9701021A0 (en) 1997-07-31
NO20016226L (no) 1997-09-08
CN1138546C (zh) 2004-02-18
RU2002122174A (ru) 2004-02-27
DZ1961A1 (fr) 2002-02-17
CN1177299A (zh) 1998-03-25
DE69630777D1 (de) 2003-12-24
HUP9702409A2 (hu) 1999-05-28
JP2002105047A (ja) 2002-04-10
HK1003623A1 (en) 1999-02-12

Similar Documents

Publication Publication Date Title
RU2196139C2 (ru) 1,4,5-тризамещенные производные имидазола, способы их получения и фармацевтическая композиция на их основе
EP0831830B1 (en) Imidazole compounds
US5716955A (en) Substituted imidazole compounds
US5739143A (en) Imidazole compounds and compositions
EP0889726B1 (en) Novel cycloalkyl substituted imidazoles
US5929076A (en) Cycloalkyl substituted imidazoles
KR19980701374A (ko) 신규 화합물(Novel Compounds)
EP0943616A1 (en) Substituted imidazole derivatives and their use as cytokine inhibitors
JP2000503302A (ja) 新規置換イミダゾール化合物
KR19990077166A (ko) 신규한 시클로알킬 치환 이미다졸
CZ219698A3 (cs) Nová substituovaná imidazolová sloučenina, způsob její přípravy, farmaceutický prostředek s jejím obsahem a způsob léčení
BG63362B1 (bg) Нови заместени имидазоли
HK1052690A (en) Process for the preparation of tosylbenzylformamides
HK1057540A (en) Pyridyl and pyrimidinyl imines as intermediates for imidazole derivatives
HK1022624B (en) Novel substituted imidazole compounds

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20050112